Showing 421-430 of 1895 results for "".
Thoughts on HIPAA
https://practicaldermatology.com/topics/practice-management/thoughts-on-hipaa/19206/Michael Sacopulos, JD discusses HIPAA compliance for aesthetic practices. (Recorded June 2013)All Things Psoriasis With Dr. April Armstrong
https://practicaldermatology.com/series/the-practical-dermatology-podcast/all-things-psoriasis-with-dr-april-armstrong/36135/The latest news and updates, plus April W. Armstrong, MD, MPH, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the current state of psoriasis treatments, what's in the pipeline, her experience in leadership positions for multiple psoriasis organizations, and more.FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.On New Therapeutics and Real Sushi
https://practicaldermatology.com/series/the-practical-dermatology-podcast/on-new-therapeutics-and-real-sushi/32849/The latest news and updates, plus E. James Song, MD, FAAD, joins Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, to discuss the 2025 outlook for new therapeutics and play "Two Truths and a Lie." Dr. Song says he has been a wrestler, a jazz musician, and a sushi cheFDA Approves Axillary Hyperhidrosis Treatment; Study Examines Biologic Outcomes in Psoriasis
https://practicaldermatology.com/series/dermwire-tv/fda-approves-axillary-hyperhidrosis-treatment-study-examines-biologic-outcomes-psoriasis/26562/In this week's DermwireTV, the FDA approves a first-of-its-kind gel for axillary hyperhidrosis; a new analysis examines how smoking, BMI, and age affect biologic outcomes in psoriasis; and the CEO of Aerolase joins us to discuss the latest trends in the aesthetic laser market.PDT in Action: New Options for Actinic Keratosis
https://practicaldermatology.com/series/pdt-in-practice/pdt-in-action-new-options-for-actinic-keratosis/20210/Dr. Joel L. Cohen, a board-certified dermatologist practicing in Denver, shares insights into the use of photodynamic therapy (PDT) in his practice and how PDT has impacted the options for the treatment of actinic keratosis.Photoprotection in Diverse Patient Populations
https://practicaldermatology.com/programs/practical-dermatology/photoprotection-in-diverse-patient-populations/18196/In part one of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Drs. Andrew Alexis, Corey Hartman, and Janiene Luke discuss photoprotection and why it matters for all patients.The Use of Lasers and Energy-Based Devices in Patients with Richly Pigmented Skin
https://practicaldermatology.com/programs/practical-dermatology/the-use-of-lasers-and-energy-based-devices-in-patients-with-richly-pigmented-skin/18199/In the last of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Andrew Alexis, MD, a dermatologist from New York City and the President of the Skin of Color Society, Corey Hartman, MD, a dermatologist in Birmingham, Alabama, and Janiene Luke, MD, a dermatoloClosing Gaps in Care for People of Color with Psoriatic Disease
https://practicaldermatology.com/programs/practical-dermatology/closing-gaps-in-care-for-people-of-color-with-psoriatic-disease/18190/Black, Hispanic, Asian, and other people of color with plaque psoriasis and psoriatic arthritis often face delayed diagnosis, misdiagnosis, and limited access to testing, treatment, and care. Determi-Nation, a new initiative sponsored by Janssen Pharmaceuticals, aims to change this. Patient advocateA Closer Look at Cibinqo for AD Management
https://practicaldermatology.com/topics/atopic-dermatitis/a-closer-look-at-cibinqo-for-ad-management/23664/Oral JAK inhibitors offer rapid onset of efficacy and some flexibility in the management of moderate to severe eczema.